Eg5抑制剂VII | 912953-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: Eg5抑制剂VII
• 英文名称: 6-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-quinolin-2-one
• 英文别名: 6-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinolin-2(1H)-one；6-[4-(Trifluoromethyl)phenyl]-3,4-dihydro-2(1H)-quinolinone
• CAS: 912953-25-4
• 化学式: C₁₆H₁₂F₃NO
• 分子量: 291.273
• InChiKey: WNVWLPPJRMIRBG-UHFFFAOYSA-N

物化性质

• 沸点：
  429.5±45.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Eg5抑制剂VII 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 氯仿 为溶剂， 反应 6.0h， 以19%的产率得到6-[4-(trifluoromethyl)phenyl]-2(1H)-quinolinone
  参考文献：
  名称：

  WO2006/113432

  摘要：

  公开号：
• 作为产物：
  描述：

  6-溴-1,2,3,4-四氢-2-喹啉酮 、 4-三氟甲基苯硼酸 在 四(三苯基膦)钯 caesium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 Eg5抑制剂VII
  参考文献：
  名称：

  [EN] ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  [FR] SULFONAMIDES N-HÉTÉROCYCLIQUES ANNELÉS AVEC GROUPEMENT DE TÊTE OXADIAZOLONE, PROCÉDÉS POUR LEUR PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS

  摘要：

  含有噁二唑酮头基的环化N-杂环磺酰胺，其制备方法及其作为药物的用途。本发明涉及含有噁二唑酮头基的环化N-杂环磺酰胺及其生理上可接受的盐和生理功能衍生物，显示出PPARδ或PPARδ和PPARα激动剂活性。所描述的是具有化合物I的结构的化合物，其中基团如定义所述，以及其生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗参与的疾病，以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。

  公开号：

  WO2009149820A1

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Abelman Matthew

  公开号：US20100113514A1

  公开（公告）日：2010-05-06

  The present invention relates to sodium channel inhibitors of Formula : in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.

  本发明涉及Formula的钠通道抑制剂：其中R1、R2、R3、R4、R5、R6和R7如上定义，并其在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。
• Compounds, Compositions, and Methods
  申请人：Adams Nicholas D.

  公开号：US20080176830A1

  公开（公告）日：2008-07-24

  Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

  本发明揭示了通过调节KSP的活性治疗细胞增殖性疾病和紊乱的有用化合物。
• ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Keil Stefanie

  公开号：US20120122853A1

  公开（公告）日：2012-05-17

  Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals The invention relates to annelated N-heterocyclic sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及具有氧代噻唑酮头基的环状N-杂环磺酰胺，以及它们的生理上可接受的盐和生理上功能衍生物，具有PPARδ或PPARδ和PPARα激动剂活性。所描述的是I式化合物，其中基团如定义所述，以及它们的生理上可接受的盐和制备过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍，以及胰岛素抵抗涉及的障碍和中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
• Fused heterocyclic compounds as ion channel modulators
  申请人：Gilead Sciences, Inc.

  公开号：US08664379B2

  公开（公告）日：2014-03-04

  The present invention relates to sodium channel inhibitors of Formula I: in which R1, R2, R3, R4, R5, R6, and R7 are as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.

  本发明涉及公式I的钠离子通道抑制剂：其中R1、R2、R3、R4、R5、R6和R7如上定义，并且涉及它们在治疗各种疾病状态中的使用，包括心血管疾病和糖尿病。
• Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
  申请人：Keil Stefanie

  公开号：US08946212B2

  公开（公告）日：2015-02-03

  Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals The invention relates to annelated N-heterocyclic sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及带有噁二唑酮头基的环状N-杂环磺酰胺，其制备方法以及它们作为药物的使用。本发明涉及的化合物是公式I中的化合物，其中基团的定义如所述，以及它们的生理上可接受的盐和生理上功能衍生物，具有PPARδ或PPARδ和PPARα激动剂活性。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗参与的疾病以及中枢和周围神经系统的脱髓鞘和其他神经退行性疾病。本发明还涉及这些化合物的生理上可接受的盐的制备方法。